Biomarkers Show Potential for Parkinson's Diagnosis

This article originally appeared here.
Share this content:
Biomarkers Show Potential for Parkinson's Diagnosis
Biomarkers Show Potential for Parkinson's Diagnosis

(HealthDay News) -- Researchers have developed a blood test that they say could help neurologists detect Parkinson's disease and track the illness as it progresses. The study was published online Feb. 2 in the Proceedings of the National Academy of Sciences.

The researchers say they've found two genetic markers that are 90 percent effective at indicating the presence of Parkinson's disease. The markers are related to how the body processes glucose and insulin, study lead author Jose Santiago, a research associate at the Chicago Medical School, told HealthDay.

The team tracked 101 people with Parkinson's and 91 healthy people. They found that gene expression changed significantly over three years in the Parkinson's patients. It's not clear whether Parkinson's causes changes in the genes or if the genes actually contribute to the development of Parkinson's, the researchers said. Both genes are associated with diabetes, and scientists suspect there may be a link between the two diseases.

More research is needed to confirm that the test works, and the researchers would like to make it more accurate. Also, it's not clear how much the test might ultimately cost. "If successful, we expect our findings will translate into a valuable diagnostic tool for Parkinson's disease," study coauthor Judith Potashkin, Ph.D., professor of cellular and molecular pharmacology at the Chicago Medical School, Rosalind Franklin University of Medicine and Science, told HealthDay.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths